In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day.
In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day.
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day.
The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In the latest trading session, Novavax (NVAX) closed at $8.55, marking a +0.53% move from the previous day.
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?
Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.